文献速递冠心病外科

孤立性冠状动脉旁路移植术中同期治疗心房颤动

Concomitant Treatment of Atrial Fibrillation in Isolated Coronary Artery Bypass Grafting.
PubMed 文献 · Ann Thorac Surg · 2023-12-13

基于美国联邦医疗保险住院索赔数据库2018至2020年数据,纳入19,524例术前心房颤动并接受孤立性冠状动脉旁路移植术的患者,比较外科消融联合左心耳封堵、单纯左心耳封堵与未治疗心房颤动的3年结局。同期治疗与3年卒中再入院减少相关,外科消融联合左心耳封堵与3年无卒中或死亡复合结局优于单纯左心耳封堵或未治疗。

要点

  • 在孤立性冠状动脉旁路移植术的心房颤动患者中,同期治疗与3年卒中再入院减少相关。
  • 外科消融联合左心耳封堵与3年生存改善相关,单纯左心耳封堵未见生存改善。
  • 外科消融联合左心耳封堵的3年无卒中或死亡复合结局优于单纯左心耳封堵或未治疗。

核心结论

  • 在因心房颤动接受孤立性冠状动脉旁路移植术的联邦医疗保险受益人中,同期治疗心房颤动与3年卒中再入院减少相关;外科消融联合左心耳封堵与3年卒中或死亡复合结局的改善优于单纯左心耳封堵或未治疗。

研究设计与样本

  • 基于美国联邦医疗保险与医疗补助服务中心住院索赔数据库,纳入2018年至2020年所有接受孤立性冠状动脉旁路移植术的心房颤动患者,共19,524例,按外科消融联合左心耳封堵(3475例,17.8%)、单纯左心耳封堵(4541例,23.3%)或未治疗心房颤动(11,508例,58.9%)分层,采用双重稳健风险调整。

主要发现

  • 与未治疗心房颤动相比,外科消融联合左心耳封堵(HR 0.86,P=0.016)与生存改善相关,而单纯左心耳封堵(HR 0.97,P=0.573)与生存改善无显著相关。
  • 外科消融联合左心耳封堵与3年无卒中或死亡复合结局优于单纯左心耳封堵(HR 0.86,P=0.033)或未治疗心房颤动(HR 0.81,P=0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Societal guidelines support concomitant management of atrial fibrillation (AF) in patients undergoing cardiac surgery. To assess real-world adoption and outcomes, this study evaluated Medicare beneficiaries with AF who underwent isolated coronary artery bypass grafting (CABG) with surgical ablation (SA) or left atrial appendage obliteration (LAAO) or both procedures in combination (SA + LAAO). METHODS: The US Centers for Medicare & Medicaid Services inpatient claims database identified all patients with AF who underwent isolated CABG from 2018 to 2020. Diagnosis-related group and International Classification of Diseases-10th revision procedure codes defined covariates for doubly robust risk adjustment. RESULTS: A total of 19,524 patients with preoperative AF who underwent isolated CABG were stratified by SA + LAAO (3475 patients; 17.8%), LAAO only (4541 patients; 23.3%), or no AF treatment (11,508 patients; 58.9%). After doubly robust risk adjustment, longitudinal analysis highlighted that concomitant AF treatment with SA + LAAO (hazard ratio [HR], 0.74; P = .049) or LAAO alone (HR, 0.75; P = . 031) was associated with a significant reduction in readmission for stroke at 3 years compared with no AF treatment. Furthermore, SA + LAAO (HR, 0.86; P = .016) but not LAAO alone (HR, 0.97; P = .573) was associated with improved survival compared with no AF treatment. Finally, SA + LAAO was associated with a superior composite outcome of freedom from stroke or death at 3 years compared with LAAO alone (HR, 0.86;, P = .033) or no AF treatment (HR, 0.81; P = .001). CONCLUSIONS: In Medicare beneficiaries with AF who underwent isolated CABG, concomitant AF treatment was associated with reduced 3-year readmission for stroke. SA + LAAO was associated with superior reduction in stroke or death at 3 years compared with LAAO alone or no AF treatment.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Mehaffey JH, Hayanga JWA, Wei LM, et al. Concomitant Treatment of Atrial Fibrillation in Isolated Coronary Artery Bypass Grafting. Ann Thorac Surg. 2023. PMID: 38101594. doi:10.1016/j.athoracsur.2023.11.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。